Jeff Stebbins

Title: Jeff Stebbins: Innovator in Diacylglycerol O-Acyltransferase Inhibitors

Introduction

Jeff Stebbins is a notable inventor based in San Diego, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of inhibitors for diacylglycerol O-acyltransferase 1 (DGAT-1). With a total of 4 patents to his name, his work is aimed at addressing various health issues related to lipid metabolism.

Latest Patents

One of Jeff Stebbins' latest patents focuses on the use of fused bicycle heterocyclic adducts of thiohydroxy pyridines or pyrimidines as DGAT-1 inhibitors. This invention is designed to treat hyperlipidemias and associated diseases. It also aims to ameliorate conditions such as high postprandial triglycerides, cardiovascular risks linked to excessive triglycerides, and insulin resistance in patients with metabolic disorders. Another patent involves compounds represented by the formula Q-G-G-G-G-Z, which can also serve as DGAT-1 inhibitors for similar health issues.

Career Highlights

Jeff Stebbins is currently employed at Metabasis Therapeutics, Inc., where he continues to innovate in the field of metabolic disorders. His work has the potential to significantly impact the treatment of conditions related to lipid metabolism.

Collaborations

He collaborates with notable colleagues such as K Raja Reddy and Serge H Boyer, contributing to a dynamic research environment focused on advancing therapeutic options.

Conclusion

Jeff Stebbins is a prominent inventor whose work on DGAT-1 inhibitors is paving the way for new treatments in metabolic health. His contributions are vital in addressing significant health challenges related to lipid metabolism.